{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(11)"],"submitter":["Kracalik I"],"pubmed_abstract":["Background
Data on medium-term outcomes in indivduals with myocarditis after mRNA COVID-19 vaccination are scarce. We aimed to assess clinical outcomes and quality of life at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults.Methods
In this follow-up surveillance study, we conducted surveys in US individuals aged 12-29 years with myocarditis after mRNA COVID-19 vaccination, for whom a report had been filed to the Vaccine Adverse Event Reporting System between Jan 12 and Nov 5, 2021. A two-component survey was administered, one component to patients (or parents or guardians) and one component to health-care providers, to assess patient outcomes at least 90 days since myocarditis onset. Data collected were recovery status"],"journal":["The Lancet. Child & adolescent health"],"pagination":["788-798"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9555956"],"repository":["biostudies-literature"],"pubmed_title":["Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study."],"pmcid":["PMC9555956"],"pubmed_authors":["Neiman A","McNamara K","Valderrama AL","Ramirez-Cardenas A","Nale C","Feyereisen M","Rao A","Shimabukuro TT","Lanier Gholston L","Solanky D","Patel S","Kabore C","Arvelo Jefferson C","Taylor A","Kracalik I","Woo J","Lehman J","Schaeffer T","Gonsahn S","Shields K","Kapella BK","Edwards K","Mazurek JM","Ruberg FL","Basavaraju SV","Kluisza N","Works K","Shay DK","Gunta J","Broder KR","Moore ML","Museru O","Barnes C","Jacobs Slifka K","Sullivan R","Bafford N","Desai M","Tran CH","Thomas K","Dulski T","Walter EB","Assefa A","Dyleski B","Moro P","Newsome K","Soslow J","Pantazides B","Tola J","Su JR","Moroney JF","Oster ME","Marquez P","Boles S","Anugwom C","Novosad S","Campbell P","Glover M","Robinson S","Creech CB","Campbell MJ","Reynolds L","Cortese MM","Stanley T","Sperling L","Thompson S","Kennebrew K","Dendy JM","Magill SS","Badger K","Law M","Collins E","Gregory T","Myocarditis Outcomes After mRNA COVID-19 Vaccination Investigators and the CDC COVID-19 Response Team","Wiersma S","McGruder H","Romanson B","Lang S","Odom E","Karol S"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study.","description":"Background
Data on medium-term outcomes in indivduals with myocarditis after mRNA COVID-19 vaccination are scarce. We aimed to assess clinical outcomes and quality of life at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults.Methods
In this follow-up surveillance study, we conducted surveys in US individuals aged 12-29 years with myocarditis after mRNA COVID-19 vaccination, for whom a report had been filed to the Vaccine Adverse Event Reporting System between Jan 12 and Nov 5, 2021. A two-component survey was administered, one component to patients (or parents or guardians) and one component to health-care providers, to assess patient outcomes at least 90 days since myocarditis onset. Data collected were recovery status","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-03T21:30:45.797Z","creation":"2025-04-03T21:30:45.797Z"},"accession":"S-EPMC9555956","cross_references":{"pubmed":["36152650"],"doi":["10.1016/S2352-4642(22)00244-9"]}}